Holen Sie sich die Stockscreener-App
4.82
4.55%
-0.23
Schlusskurs vom Vortag:
$5.05
Offen:
$5.05
24-Stunden-Volumen:
744.59K
Relative Volume:
0.89
Marktkapitalisierung:
$378.47M
Einnahmen:
$531.00K
Nettoeinkommen (Verlust:
$-99.96M
KGV:
-2.199
EPS:
-2.1919
Netto-Cashflow:
$-98.96M
1W Leistung:
+2.77%
1M Leistung:
+16.71%
6M Leistung:
-54.27%
1J Leistung:
+5.01%
1-Tages-Spanne:
$4.635
$5.09
1-Wochen-Bereich:
$4.525
$5.38
52-Wochen-Spanne:
$3.60
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.82 | 378.47M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-15 | Eingeleitet | Guggenheim | Buy |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
LXEOLexeo Therapeutics Inc Dividends - Finviz
Have Insiders Sold Lexeo Therapeutics Shares Recently? - simplywall.st
Have Lexeo Therapeutics Insiders Been Selling Stock? - 富途牛牛
Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update? - Yahoo Finance
Lexeo Therapeutics CMO sells $98,592 in shares By Investing.com - Investing.com South Africa
Lexeo Therapeutics CMO sells $98,592 in shares - Investing.com
Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock By Investing.com - Investing.com Australia
Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock - Investing.com
Form 4 Lexeo Therapeutics Inc For: 1 July By Investing.com - Investing.com India
RSU grant and tax-cover share sale by Lexeo (LXEO) chief financial officer - Stock Titan
Lexeo Therapeutics (LXEO) COO reports stock award and small tax-related sale - Stock Titan
Lexeo Therapeutics (LXEO) CMO awarded 55K shares and sells 22K to cover RSU taxes - Stock Titan
Lexeo Therapeutics (LXEO) CEO logs RSU grant and tax-driven share sale - Stock Titan
Form 144 Lexeo Therapeutics For: 1 July By Investing.com - Investing.com UK
LXEO (NASDAQ) Form 144: Proposed resale of 4,666 vested shares via Fidelity - Stock Titan
[144] Lexeo Therapeutics, Inc. SEC Filing - Stock Titan
LXEO (NASDAQ: LXEO) director files Form 144 proposing sale of 25,947 shares - Stock Titan
Top Brass at Lexeo Therapeutics Quietly Unload a Chunk of Company Stock - TipRanks
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
Form 4 Lexeo Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa
Lexeo Shareholders Reelect Directors, Ratify KPMG Auditor - TipRanks
Lexeo Therapeutics (NASDAQ: LXEO) investors approve directors and ratify KPMG auditor - Stock Titan
Lexeo Therapeutics (LXEO) director awarded options on 35,000 shares at $4.70 - Stock Titan
Lexeo Therapeutics (LXEO) director receives 35,000 options at $4.70 - Stock Titan
Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70 - Stock Titan
Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70 strike - Stock Titan
Lexeo Therapeutics (LXEO) director receives grant of 35,000 stock options at $4.70 - Stock Titan
Lexeo Therapeutics, Inc. Actuals & Estimates (NASDAQ:LXEO) - TradingView
LXEO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Lexeo Therapeutics, Inc. – NASDAQ:LXEO - TradingView
Price to book forward of Lexeo Therapeutics, Inc. – NASDAQ:LXEO - TradingView
Enterprise value to revenue forward of Lexeo Therapeutics, Inc. – NASDAQ:LXEO - TradingView
Price to earnings forward of Lexeo Therapeutics, Inc. – NASDAQ:LXEO - TradingView
LEXEO THERAPEUTICS INC (LXEO) Stock Chart - ChartMill
Lexeo Therapeutics Price Target Cut to $9.00/Share From $12.00 by JP Morgan - Moomoo
LXEO Maintained by JP Morgan -- Price Target Lowered to $9.00 - GuruFocus
Lexeo Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
J.P. Morgan Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Announces Target Price $9 - Moomoo
Lexeo Therapeutics’s LX2006 Has A Viable Regulatory Pathway And Timeline (NASDAQ:LXEO) - Seeking Alpha
Lexeo Therapeutics Shares Climb Following FDA Breakthrough Therapy Designation - MSN
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Lexeo Therapeutics Inc (LXEO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Insiders In Lexeo Therapeutics Left Out From 21% Price Rise After Disposing Stock - 富途牛牛
Lexeo Therapeutics Inc (LXEO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexeo Therapeutics Inc (LXEO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexeo Therapeutics Inc (LXEO) Institutional Confidence - TradingKey
Lexeo Therapeutics Inc (LXEO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexeo Therapeutics Inc (LXEO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexeo Therapeutics Inc (LXEO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexeo publishes phase I/II data for gene therapy LX2006 By Investing.com - Investing.com South Africa
Lexeo publishes phase I/II data for gene therapy LX2006 - Investing.com
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexeo Therapeutics Inc-Aktie (LXEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Otero Jose Manuel | Chief Operating Officer |
Jul 01 '26 |
Sale |
4.48 |
4,666 |
20,904 |
137,482 |
| Bhalla Narinder Pal | Chief Medical Officer |
Jul 01 '26 |
Sale |
4.42 |
22,306 |
98,593 |
82,194 |
| Townsend Richard Nolan | Chief Executive Officer |
Jul 01 '26 |
Sale |
4.48 |
25,947 |
116,243 |
377,817 |
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):